Last fall, the Centers for Medicare & Medicaid Services (CMS) released its final rule implementing the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The final rule provides Medicare incentives to reward quality and value—not volume—through the use of alternative payment models.
Washington, DC—The use of biosimilars offers great potential to reduce healthcare spending while expanding access to effective therapies for conditions such as rheumatoid arthritis. The numerous issues related to the development, regulation, reimbursement, and marketing of these agents were addressed by Candida Fratazzi, MD, President, BBCR Consulting, Cambridge, MA, at the 2016 Annual Meeting of the American College of Rheumatology.

Results 1 - 2 of 2
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management